Co-Targeting BCL-XL and BCL-2 by PROTAC 753B Eliminates Leukemia Cells and Enhances Efficacy of Chemotherapy by Targeting Senescent Cells

Investigators reported pre-clinical single-agent activity of 753B against different leukemia subsets. 753B effectively reduced cell viability and induced dose-dependent degradation of BCL-XL and BCL-2 in a subset of hematopoietic cell lines, AML primary samples, and in vivo PDX AML model.